In the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7, 2003), Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin II Receptor Blockers (ARBs) were recommended as initial or add-on pharmacological therapy particularly for patients with CKD [5, 7]. Here, ACE is linked to hypertensive disorder.